Orchid Pharma Ltd (ORCHPHARMA)
₹944.00
Mkt cap
₹5,717 Cr
P/E ratio
317.00
P/B
3.72
Div yield
0.00%
ROE
1.35%
ROCE
1.73%
EPS (TTM)
₹2.98
Book value
₹254
52W range
482–1,101
Sector
Healthcare
Price history
Previous close
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]
NSE ORCHPHARMABSE 524372
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−14.29% from high₹944
₹482+95.67% from low₹1,101
Current
₹944.00
Prev close
₹958.00
Day
−1.46%
Price performance
1D
−1.46%
1W
−2.77%
1M
−5.77%
3M
+9.79%
6M
+67.01%
1Y
+29.53%
YTD
+18.79%
Financials
Revenue, profit & margin
P/E ratio
317.0×
ORCHPHARMA is 833% above the sector median of 34.0×
ORCHPHARMA317.0×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 182.92 | 198.76 | 220.59 | 217.10 | 244.41 | 222.70 | 217.34 | 237.48 | 263.19 | 193.52 | 207.27 | 368.33 | 304.17 | |
| Expenses | 160.78 | 175.46 | 185.21 | 188.19 | 211.92 | 192.36 | 190.97 | 209.49 | 268.84 | 194.99 | 205.71 | 338.17 | 290.17 | |
| Operating Profit | 22.14 | 23.30 | 35.38 | 28.91 | 32.49 | 30.34 | 26.37 | 27.99 | -5.65 | -1.47 | 1.56 | 30.16 | 14.00 | |
| OPM % | 12.10% | 11.72% | 16.04% | 13.32% | 13.29% | 13.62% | 12.13% | 11.79% | -2.15% | -0.76% | 0.75% | 8.19% | 4.60% | |
| Other Income | 1.89 | 8.36 | 7.62 | 13.36 | 7.57 | 7.52 | 8.49 | 3.90 | 11.57 | 10.77 | -1.50 | 7.55 | 1.83 | |
| Interest | 5.55 | 3.80 | 3.54 | 3.47 | 3.50 | 3.33 | 3.80 | 3.92 | 2.28 | 3.73 | 3.18 | 1.96 | 2.23 | |
| Depreciation | 7.71 | 7.84 | 9.27 | 8.42 | 8.44 | 8.63 | 8.61 | 8.87 | 10.53 | 8.90 | 9.03 | 10.90 | 10.95 | |
| Profit before tax | 10.77 | 20.02 | 30.19 | 30.38 | 28.12 | 25.90 | 22.45 | 19.10 | -6.89 | -3.33 | -12.15 | 24.85 | 2.65 | |
| Tax % | 0.00% | 0.00% | 0.00% | -10.27% | -0.53% | 0.00% | 0.00% | -0.21% | 0.00% | 0.00% | 0.00% | 0.00% | 2.64% | |
| Net Profit | 9.40 | 19.80 | 29.43 | 32.96 | 29.35 | 27.24 | 20.78 | 22.29 | -5.69 | -5.72 | -12.61 | 25.84 | 3.22 | |
| EPS in Rs | 1.85 | 3.90 | 5.80 | 6.50 | 5.79 | 5.37 | 4.10 | 4.39 | -1.12 | -1.13 | -2.49 | 5.09 | 0.63 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202669.84%Promoter
Promoters69.84%
FIIs0.80%0.07
DIIs20.75%0.51
Public8.62%0.42
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| ORCHPHARMA | ₹954.65 | 316.55 | 5,717 | 0.00% | 3 | +156.59% | 304 | +15.57% | 1.73% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2019bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2013nseAnnual Report 2013bseAnnual Report 2012bseAnnual Report 2012nse
Concall transcripts48
RECNov 2023TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptJun 2025PPTJun 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024RECMay 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Change in Management 3 Sep - Board appointed Arjun Dhanuka as Whole-Time Director for five years and fixed AGM on Sept. 29, 2026.Board Meeting Outcome for Outcome Of Board Meeting 3 Sep - Board appointed Arjun Dhanuka as Whole-Time Director for five years; AGM on September 29, 2026.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 24 Aug - Transcript of Analysts/Investors earning call held with public at large on August 21, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 21 Aug - Orchid Pharma uploaded audio recording of Q1 FY27 earnings call held on August 21, 2026.Announcement under Regulation 30 (LODR)-Investor Presentation 20 Aug - Investors Presentation-Quarter 1 of F.Y.2026-27, ended on June 30, 2026.